... / ... / ... / Researchers / prof. dr. Charles Boucher

prof. dr. Charles Boucher

Charles Boucher received his medical degree cum laude from the Amsterdam Medica Charles Boucherl Center (University of Amsterdam)  and a PhD in Clinical Virology from the University of Amsterdam, he headed the AMC's antiviral therapy laboratory and later became the assistant professor/ clinical virologist at  the University Medical Center Utrecht ).
He is a Professor in clinical virology at the Erasmus Medical Centre (Erasmus University) in Rotterdam since 2002, he is the director of the Querido Honours college, and chairs the HIV & Hepatitis Masterclasses for Dutch Specialists in Training.
He is the co-founder and is the Chair of the European Society for antiviral Research (ESAR).
Prof. Boucher is founder and scientific director of Virology Education, a medical education company focussing on the initiation and organization of real-time and online platforms for international interchange, knowledge-sharing and education for medical professionals. He co-organizes a number of international meetings.
Presently, Dr. Boucher's translational research encompasses the evolution of HIV, drug resistance and therapy/cure in relation to pathogenesis and clinical progression and has expanded to include the relationship of viral pathogenesis (HIV, HBV, HCV, Influenza) transmission, epidemiology and (modelling of) public health based interventions. He has published over 300 peer reviewed publications and has reviewed 27 scientific reviews of journals and grants.

Selection of Publications:

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study. 
van der Vries E, Ip DK, Cowling BJ, Zhang JD, Tong X, Wojtowicz K, Schutten M, Boucher, C.A.B. J Infect Dis.  2016 Jan 15;213(2):183-90.

Small Molecule Inhibitors of BAF; A promising family of compounds in HIV-1 latency reversal. 
Stoszko M, Crignis E.  de, Rokx C, Khalid M, Lungu C, Palstra R, Kan T, Boucher, C.A.B., Verbon A, Dykhuize E, Mahmoudi T. EBioMedicine 2015 Nov 27;3:108-21

First-line HIV therapy shall not fail.  Lancet HIV
Boucher, C.A.B., Vella S. Lancet HIV.  2016 Mar;3(3):e108-9.

Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study (IRIS).
Lina B, Boucher, C.A.B., Osterhaus A, Monto A, Schutten M, Whitley R, Nguyven-van Tam J. Influenza other Respi Viruses. 2018;1-12.

Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategies
Van de Vijver D, Boucher, C.A.B. Curr Opin HIV AIDS 2017 Dec 20

Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy.
Boerekamps A, Berk van den G, Fanny L, Leyten E, Kasteren van M, Eeden van A, Posthouwer D, Claassen M, Dofferhoff A, Verhagen D, Bierman W, Lettinga K, Kroon F, Delsing C, Groeneveld P, Soetekouw R, Peters E, Hullegie S, Popping S, Vijver van de  D, Boucher, C.A.B., Arends J, Rijnders B. Clin Infect Dis. 2017 Nov 23

Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance
Letter to the editor.Tienen van C, Vijver van de D, Noori T, Sönnerborg A, Boucher, C.A.B. Euro Surveill. 2017 Mar 16;22(11).